Invention Grant
- Patent Title: Anti CD4 antibodies to prevent in particular graft-versus-host-disease (GVHD)
-
Application No.: US15786724Application Date: 2017-10-18
-
Publication No.: US10577588B2Publication Date: 2020-03-03
- Inventor: Stephan Fricke , Frank Emmrich , Nadja Hilger
- Applicant: Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.
- Applicant Address: DE München
- Assignee: Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.
- Current Assignee: Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.
- Current Assignee Address: DE München
- Agency: Clark & Elbing LLP
- Priority: EP10015236 20101202
- Main IPC: C07K16/28
- IPC: C07K16/28 ; C12N5/077 ; C12N5/078 ; A61K35/28 ; C12N5/00 ; A61K35/12 ; A61K39/00

Abstract:
The present invention relates to, among others, an in vitro method of modifying a cell graft containing immune cells comprising the steps of incubating a cell graft containing immune cells with an anti CD4 antibody wherein said incubating is carried out for from 1 minute to 7 days, b) removing unbound antibody from said graft; as well as to corresponding modified grafts and uses. The invention further relates to the modification of antibodies reactive to the CD4 human leukocyte antigen to provide anti-CD4 antibodies that have a reduced number of potential T-cell epitopes but retain the ability to bind to CD4, such as to an anti human CD4-antibody comprising a heavy chain immunoglobulin variable domain (VH) and a light chain immunoglobulin variable domain (VL), wherein at least one T cell epitope located outside the CDRs of said immunoglobulin variable domains is removed from said immunoglobulin variable domains. Preferably, the specificity and mode of action of the anti-CD4 antibodies are not affected by the modification(s).
Public/Granted literature
- US20180051254A1 ANTI CD4 ANTIBODIES TO PREVENT IN PARTICULAR GRAFT -VERSUS - HOST - DISEASE (GVHD) Public/Granted day:2018-02-22
Information query